Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar-Apr;33(2):125-133.
doi: 10.20524/aog.2020.0457. Epub 2020 Feb 12.

Inflammatory bowel disease pathobiology: the role of the interferon signature

Affiliations
Review

Inflammatory bowel disease pathobiology: the role of the interferon signature

Nicolaos-Panagiotis Andreou et al. Ann Gastroenterol. 2020 Mar-Apr.

Abstract

The pathogenesis of inflammatory bowel disease (IBD) is still unclear, but includes both inflammatory and autoimmune reactions. Current methodological approaches could better elucidate the cytokine pathways and the genetics involved in the etiopathogenesis of this disease. Interferons (IFNs) are cytokines that play a key role in autoimmune/inflammatory disorders because of their pro- and anti-inflammatory properties as well as their immunoregulatory functions. An increased expression of IFN-regulated genes, widely known as an IFN signature, has been reported in blood and tissue from patients with autoimmune disorders. In this review, we present the function as well as the clinical and therapeutic potential of the IFN signature. Current data demonstrate that the IFN signature can be used as a biomarker that defines disease activity in autoimmune diseases, although this has not been thoroughly studied in IBD. Consequently, further investigation of the IFN signature in IBD would be essential for a better understanding of its actions.

Keywords: Inflammatory bowel disease; interferon; interferon signature.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

References

    1. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome:an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–749. - PubMed
    1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54. - PubMed
    1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078. - PMC - PubMed
    1. Peyrin-Biroulet L, Loftus EV, Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–297. - PubMed
    1. Thomas A, Lodhia N. Advanced therapy for inflammatory bowel disease:a guide for the primary care physician. J Am Board Fam Med. 2014;27:411–420. - PubMed

LinkOut - more resources